This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Nutrition/ Malnutrition  • Ophthalmology  • Macular Degeneration  • Women's Health  • Women's Health, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Seeing Through the Shadows

Christopher O. Phillips, MD, MPH; Eve J. Higginbotham, MD

Arch Intern Med. 2009;169(13):1180-1182.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the February 23, 2009, issue of the Archives, Christen et al¹ reported the results of a large clinical trial evaluating the effects of a combination of folic acid, pyridoxine hydrochloride (vitamin B₆), and cyanocobalamin (vitamin B₁₂) on the development of age-related macular degeneration (AMD). This report, the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS), was derived from the larger, previously published Women's Antioxidant Cardiovascular Study (WACS), which initially enrolled 8171 female participants (mean [SD] age, 62.8 [8.8] years) with preexisting cardiovascular disease (CVD) or 3 or more coronary risk factors to investigate the efficacy of ascorbic acid (vitamin C), vitamin E, beta carotene, or placebo on cardiovascular outcomes.^2-3

This recent report by Christen et al¹ assessed the risk of developing AMD among a subset of participants in the WAFACS. A cohort of 5205 female subjects who . . . [Full Text of this Article]

WHY ARE THE FINDINGS FROM WAFACS IMPORTANT?


IDENTIFICATION AND DIAGNOSIS OF AMD

GENETIC FACTORS

TREATMENT OPTIONS

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?